Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Graphic Communications Local 1B Health & Welfare Fund "A" et al v. CVS Caremark Corporation et al
Case Number:
0:09-cv-02203
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bailey & Glasser
- Bassford Remele
- Dorsey & Whitney
- Faegre Drinker
- Felhaber Larson
- Foley & Lardner
- Fredrikson & Byron
- Jones Day
- Messerli & Kramer
- Nilan Johnson
- Stinson LLP
- Taft Stettinius
- Varnum LLP
Companies
Sectors & Industries:
-
November 25, 2009
Wal-Mart, CVS Win Bid To Toss Drug Overcharge Suit
A federal judge has dismissed without prejudice a putative class action brought by employee health funds accusing Walgreen Co., CVS Pharmacy Inc., Wal-Mart Stores Inc. and others of overcharging customers for generic drugs.
-
September 28, 2009
CVS, Wal-Mart Seek Toss Of Drug Overcharge Action
CVS Pharmacy Inc., Walgreen Co., Wal-Mart Stores Inc. and others have asked a judge to dismiss a proposed class action accusing them of overcharging for generic drugs by not passing along discounts to consumers.
-
August 31, 2009
CVS, Others Hit With Suit Over Generics Prices
Two Minnesota-based employee health funds have accused CVS Pharmacy Inc., Walgreen Co., Wal-Mart Stores Inc. and other pharmacies of overcharging customers for generic drugs, illegally hiking up prices instead of passing on the discounts they receive in the acquisition of generics to consumers.